CISI FIN (06058.HK): USD 11.56 million perpetual securities purchase
- The securities are issued by MTR Corporation (C.I.) Limited and guaranteed on a subordinated basis by MTR Corporation Limited, with USD 1.5 billion principal and a 5.625% coupon, with no maturity.
NewTimeSpace News: On 3 November 2026, China Industrial Securities International Financial Group Limited (stock code: 06058) said its indirect wholly-owned subsidiary CISI Investment bought perpetual securities with a total principal of USD 11,558,000 (about HKD 90,730,300) on the open market between 9 June and 30 October 2026, at a total consideration of about USD 11,788,172 (about HKD 92,537,147) funded from internal resources. The securities are issued by MTR Corporation (C.I.) Limited and irrevocably and unconditionally guaranteed on a subordinated basis by MTR Corporation Limited, with a total principal of USD 1.5 billion and a coupon of 5.625% per annum with no maturity date.
As the standalone ratios for this purchase are below 5% but one ratio exceeds 5% and is below 25% when aggregated with previous purchases, the transaction is discloseable under Chapter 14, with reporting and announcement required but shareholder approval exempt.
- CISI FIN (06058.HK): Discloseable Transaction — Subsidiary Disposes of USD 20.15 Million Notes, Recording a Gain of About USD 165,407
- CISI FIN(06058.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at HKD 137.75 million, YoY increase of 33.82%
- Offshore Trust Insight | MICOT PHARMA-B (02335.HK) First-Half R&D Expenses Up 215.9% YoY, Cumulative Decline of About 46% Since Stock Connect Inclusion
- HK Recently Listed Stocks Watch | MICOT PHARMA-B (02335.HK): 1H R&D Expenses Up 215.9% YoY, 24.681 Million Cornerstone Lock-up Shares to Be Unlocked on December 24
- MICOT PHARMA-B (02335.HK): H shares included in eligible list under Stock Connect
